收费全文 | 242149篇 |
免费 | 30326篇 |
国内免费 | 8828篇 |
耳鼻咽喉 | 3077篇 |
儿科学 | 2223篇 |
妇产科学 | 5573篇 |
基础医学 | 16873篇 |
口腔科学 | 2602篇 |
临床医学 | 20480篇 |
内科学 | 28070篇 |
皮肤病学 | 1491篇 |
神经病学 | 2656篇 |
特种医学 | 6877篇 |
外国民族医学 | 271篇 |
外科学 | 34678篇 |
综合类 | 32264篇 |
现状与发展 | 39篇 |
一般理论 | 3篇 |
预防医学 | 12187篇 |
眼科学 | 369篇 |
药学 | 17054篇 |
163篇 | |
中国医学 | 6032篇 |
肿瘤学 | 88321篇 |
2024年 | 764篇 |
2023年 | 5130篇 |
2022年 | 10011篇 |
2021年 | 12947篇 |
2020年 | 12015篇 |
2019年 | 10735篇 |
2018年 | 10311篇 |
2017年 | 10641篇 |
2016年 | 11575篇 |
2015年 | 13258篇 |
2014年 | 19768篇 |
2013年 | 19524篇 |
2012年 | 15697篇 |
2011年 | 16066篇 |
2010年 | 11847篇 |
2009年 | 11822篇 |
2008年 | 12187篇 |
2007年 | 11505篇 |
2006年 | 10030篇 |
2005年 | 8244篇 |
2004年 | 6802篇 |
2003年 | 5651篇 |
2002年 | 4820篇 |
2001年 | 4436篇 |
2000年 | 3748篇 |
1999年 | 3148篇 |
1998年 | 2665篇 |
1997年 | 2325篇 |
1996年 | 1952篇 |
1995年 | 1842篇 |
1994年 | 1568篇 |
1993年 | 1183篇 |
1992年 | 1042篇 |
1991年 | 980篇 |
1990年 | 734篇 |
1989年 | 675篇 |
1988年 | 582篇 |
1987年 | 485篇 |
1986年 | 338篇 |
1985年 | 434篇 |
1984年 | 373篇 |
1983年 | 248篇 |
1982年 | 252篇 |
1981年 | 218篇 |
1980年 | 209篇 |
1979年 | 139篇 |
1978年 | 99篇 |
1977年 | 84篇 |
1976年 | 76篇 |
1975年 | 48篇 |
Areas covered: We review the latest clinical data regarding the PARP inhibitor rucaparib in ovarian cancer, provide an update on the evolving landscape of PARP inhibition in ovarian cancer, and summarize avenues of ongoing and future research.
Expert opinion: All eligible patients should be offered a PARP inhibitor. SOLO1 trial results demonstrated an unprecedented benefit maintenance with PARP inhibitors in first line. Results from trials evaluating PARP inhibitors as maintenance in first line regardless of BRCA status and from trials evaluating combinatorial strategies are eagerly awaited. 相似文献
Area covered: The current review is provided to update recent developments in the clinical application of cyclin/CDK inhibitors to breast cancer with a focus on the anti-tumor immune response.
Expert opinion: The cyclin D1 gene encodes the regulatory subunit of a proline-directed serine-threonine kinase that phosphorylates several substrates. CDKs possess phosphorylation site selectivity, with the phosphate-acceptor residue preceding a proline. Several important proteins are substrates including all three retinoblastoma proteins, NRF1, GCN5, and FOXM1. Over 280 cyclin D3/CDK6 substrates have b\een identified. Given the diversity of substrates for cyclin/CDKs, and the altered thresholds for substrate phosphorylation that occurs during the cell cycle, it is exciting that small molecular inhibitors targeting cyclin D/CDK activity have encouraging results in specific tumors. 相似文献
Background
The objective of the study was to evaluate the outcomes of clinically localized prostate cancer treated with prostatectomy versus radiation therapy within the context of a prospective prostate cancer screening study.Patients and Methods
Within the PLCO (Prostate, Lung, Colorectal, and Ovary) trial, patients who were diagnosed with clinically localized prostate cancer and subsequently received treatment with prostatectomy or radiation therapy (with or without hormonal treatment) were included. Univariate and multivariate Cox regression analyses were then performed to determine factors affecting overall and prostate cancer-specific survival. Factors with P < .05 in univariate analysis were included in the multivariate analysis.Results
A total of 3953 patients were included in the current analysis. These included 2044 patients treated with prostatectomy and 1909 patients treated with radiation therapy with or without hormonal treatment. In an adjusted multivariate analysis for factors affecting overall survival, prostatectomy was associated with better overall survival compared with radiation therapy (hazard ratio, 0.548; 95% confidence interval [CI], 0.440- 681; P < .001). Likewise, in an adjusted multivariate analysis for factors affecting prostate cancer-specific survival, prostatectomy was associated with better prostate cancer-specific survival compared with radiation therapy (hazard ratio, 0.485; 95% CI, 0.286- 0.822; P = .007). Similar findings were found with propensity score matching and repeating the same analyses on the post-matching cohort.Conclusion
Prostatectomy seems to predict better overall and prostate cancer-specific survival compared with radiation therapy among patients with clinically localized prostate cancer diagnosed within the PLCO trial. 相似文献Areas covered: This review covers the mechanism of action, safety and efficacy of sacituzumab govitecan in patients with previously treated, metastatic TNBC. Additionally, efficacy data in other epithelial malignancies is included based on a PubMed search for ‘sacituzumab govitecan’ and ‘clinical trial’.
Expert opinion: Sacituzumab govitecan has promising anti-cancer activity in patients with metastatic TNBC previously treated with at least two prior lines of systemic therapy based on a single arm Phase I/II clinical trial. A confirmatory Phase III randomized clinical trial is ongoing. Sacituzumab govitecan has a manageable side effect profile, with the most common adverse events being nausea, neutropenia, and diarrhea. The activity of sacituzumab govitecan likely extends beyond TNBC with promising early efficacy data in many other epithelial cancers, including hormone receptor-positive breast cancer. 相似文献